PerkinElmer

The firm's Discovery and Analytical Solutions business revenues grew 1 percent year over year, while its Diagnostics revenues more than doubled.

The company anticipates total revenues of $3.9 billion for 2020, including $1 billion from its COVID-19-related business.

The company also said that organic revenues in the quarter are expected to improve 63 percent, while EPS is expected to be at least $2.88.

The deal will enable PerkinElmer to grow its infectious disease testing portfolio to include latent tuberculosis detection, it said.

The firm said there was "very high agreement" between results obtained with the test and with reference PCR tests for SARS-CoV-2 and influenza A/B.

Sanyou will use the cell line in the development of preclinical antibody drug projects and to support its customers' human biotherapeutic products.

The next-generation sequencing-based panel comprises more than 50 genes and disorders known to cause hereditary anemias, such as pyruvate kinase deficiency.

The assay can be used to pool up to five specimens collected from individuals suspected of having COVID-19 or from asymptomatic patients.

The deal allows PerkinElmer to expand its portfolio of automated life sciences discovery and applied genomics products to include gene editing and gene modulation tools.